Fundraise

Xellar raises tens of millions in strategic round, pushing 2026 haul to ~$56M

What's the deal? Xellar Biosystems, a US-based startup combining organ-on-a-chip technology with AI for drug discovery, has closed a strategic round of tens of millions of yuan, backed by Shanghai Guotou Xiandao and the CSPCDealroom has a profile for this one. Try Dealroom → Guofang Fund. It is the company's third raise of 2026, following a US$27.5M Series A and a nearly US$27.5M Series A+.

Why now? The round rides a wave of capital flowing into AI life sciences in China, where organ chips, organoids, and automated labs are increasingly seen as the way to generate the real biological data AI models need. Xellar's year-to-date fundraising now totals roughly US$55M.

What's the endgame? Founded in Boston in 2021 by a team drawn from multinational drugmakers, Harvard, and MIT, Xellar runs a "3D Bio Intelligence" platform. Its pitch is a "wet-dry loop": organ-chip experiments generate human-derived data, AI analyses the biology and predicts outcomes, and those predictions guide the next round of experiments.

The new money will deepen that platform — combining organ chips, AI, and lab automation to build what the company calls infrastructure for next-generation drug development.

Who's backing it? The two new investors bring state and pharma capital. Shanghai Guotou Xiandao manages Shanghai's biomedicine, chip, and AI industry funds, with over US$12.4B under management. The CSPC Guofang Fund, backed by drugmaker CSPC, has total committed capital of US$1.39B.

What could go wrong? Organ-chip technology remains early-stage. Founder Xie Xin says Xellar earns revenue mainly through platform-driven research partnerships, but moving from technical validation to large-scale adoption by pharma companies still requires solving standardisation, data reliability, and cost. The round funds the platform; it does not yet prove improved drug-discovery efficiency.

The signal: Regulators on both sides of the Pacific are warming to the approach — the US Food and Drug Administration published a 2025 roadmap to cut animal testing, and China's drug regulator launched a pilot for new-method research in September. "Whoever controls biological data infrastructure becomes the gateway to the next-generation drug-development operating system," Xie says (translated from Chinese). This round is a bet on that thesis.

Read more: sohu.com

Image credit: Generated with Gemini

More top stories